Cerebral Amyloid Burden and Hoehn and Yahr Stage 3 Scoring in Parkinson Disease.

BACKGROUND Progression to Hoehn and Yahr (HY) stage 3 marks the transition to advanced disease staging and disability in Parkinson disease (PD). OBJECTIVE/METHODS We conducted a case-control study of 36 PD subjects at HY stage 2.5 or 3, with groups matched for gender, age, and disease duration. Positron Emission tomography (PET) imaging included dihydrotetrabenazine [11C]DTBZ and Pittsburgh Compound B [11C]PiB. RESULTS Subjects with HY 2.5 differed from HY 3.0 in mean cortical PiB distribution volume ratio (1.14 vs. 1.23; Wilcoxon two-sample Z = 2.36, p = 0.024) but not striatal DTBZ PET. CONCLUSION Cortical amyloid burden differentiates subjects below and at HY stage 3. These results suggest that cortical amyloid accumulation influences the transition from HY2.5 to HY3 and that cortical amyloidopathy may be a therapeutic target in PD.

[1]  R. Barker,et al.  Vascular disease and vascular risk factors in relation to motor features and cognition in early Parkinson's disease , 2016, Movement disorders : official journal of the Movement Disorder Society.

[2]  R. Albin,et al.  Striatal and Cortical β‐Amyloidopathy and Cognition in Parkinson's Disease , 2016, Movement disorders : official journal of the Movement Disorder Society.

[3]  Stanley Fahn,et al.  Clinicopathological characteristics of freezing of gait in autopsy‐confirmed Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[4]  Nick C Fox,et al.  Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials , 2015, Neurology.

[5]  Mark P. MacEachern,et al.  Amyloid deposition in Parkinson's disease and cognitive impairment: A systematic review , 2015, Movement disorders : official journal of the Movement Disorder Society.

[6]  T. Robbins,et al.  The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[7]  Jeffrey M. Hausdorff,et al.  Gray matter atrophy distinguishes between Parkinson disease motor subtypes , 2013, Neurology.

[8]  R. Albin,et al.  β‐amyloid and postural instability and gait difficulty in Parkinson's disease at risk for dementia , 2013, Movement disorders : official journal of the Movement Disorder Society.

[9]  W. Jagust,et al.  Coronary risk correlates with cerebral amyloid deposition , 2012, Neurobiology of Aging.

[10]  Thomas Foltynie,et al.  The natural history of treated Parkinson's disease in an incident, community based cohort , 2011, Journal of Neurology, Neurosurgery & Psychiatry.

[11]  V. Sossi,et al.  Age‐specific progression of nigrostriatal dysfunction in Parkinson's disease , 2011, Annals of neurology.

[12]  A. Lozano,et al.  The most cited works in Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[13]  Matthias Reimold,et al.  [11C]PIB binding in Parkinson's disease dementia , 2008, NeuroImage.

[14]  J. Jankovic,et al.  Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Process, format, and clinimetric testing plan , 2007, Movement disorders : official journal of the Movement Disorder Society.

[15]  W. Poewe,et al.  Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations The Movement Disorder Society Task Force on rating scales for Parkinson's disease , 2004, Movement disorders : official journal of the Movement Disorder Society.

[16]  G. Stebbins,et al.  Differential progression of motor impairment in levodopa‐treated Parkinson's disease , 2000, Movement disorders : official journal of the Movement Disorder Society.

[17]  E. van der Velde,et al.  Clinical course of patients with idiopathic Parkinson's disease , 1996, Movement disorders : official journal of the Movement Disorder Society.

[18]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[19]  M. Hoehn,et al.  Parkinsonism , 1967, Neurology.

[20]  J. Unterrainer,et al.  Measuring the progression of idiopathic Parkinson's disease with [123I] β-CIT SPECT , 2000, Journal of Neural Transmission.